Atezolizumab is a humanized IgG1 monoclonal anti-PD-L1 antibody which blocks PD-L1-PD-1 and PD-L1-B7-1 interactions, resulting in the restoration of anti-tumor T-cell activity and enhanced T-cell priming. Here, CD274 is linked to neoplasm.